Kamada Ltd. announced that Kedrion has exercised its option to extend the distribution agreement between the parties in the U.S. for KEDRAB(R) (R babies Immune Globulin [Human), which is indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. The current agreement now extends through March 2026, and the companies are in discussions to potentially further expand the scope of the collaboration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,898 ILa | +1.61% |
|
-1.20% | -14.77% |
May. 08 | Transcript : Kamada Ltd., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Kamada Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.77% | 291M | |
+0.82% | 91.38B | |
-3.16% | 38.68B | |
-9.63% | 33.58B | |
+72.31% | 27.84B | |
-12.63% | 16.05B | |
-0.16% | 13.48B | |
-9.38% | 11.73B | |
+172.59% | 10.74B | |
-49.44% | 10.39B |
- Stock Market
- Equities
- KMDA Stock
- News Kamada Ltd.
- Kamada Ltd. Announces Kedrion Exercised Its Option for Two-Year Extension of Kedrion Distribution Agreement in the U.S